Physician profile
Taylor J Moore
NPI 1033420690
$5,520.26
in general payments reported to CMS, 2019-2025
28 companies · $806 in 2025
The $806 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,270 · 2020: $778 · 2021: $686 · 2022: $713 · 2023: $639 · 2024: $628 · 2025: $806.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,073.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,072.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,569.32 | 2019-2025 | Repatha, Otezla, Repatha |
| Lilly USA, LLC | $803.48 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $668.33 | 2019-2025 | Farxiga, Breztri |
| Novo Nordisk INC | $519.93 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $402.34 | 2019-2024 | Spiriva Respimat, Jardiance |
| Janssen Pharmaceuticals, INC | $197.65 | 2019-2024 | Xarelto |
| Pfizer INC. | $143.58 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $139.87 | 2019-2023 | Eliquis |
| Abbvie INC. | $139.81 | 2021-2025 | |
| Preventric Diagnostics, INC. | $135.04 | 2021 | |
| Boston Scientific Corporation | $109.11 | 2019-2022 | |
| Allergan, INC. | $96.26 | 2020 | |
| Novartis Pharmaceuticals Corporation | $73.36 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $71.27 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $52.66 | 2023-2024 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $52.51 | 2025 | Tymlos |
| Takeda Pharmaceuticals U.S.A., INC. | $48.48 | 2019-2022 | |
| Glaxosmithkline, LLC. | $42.01 | 2022-2023 | Trelegy Ellipta |
| Astellas Pharma US INC | $40.80 | 2019-2024 | Veozah |
| Phathom Pharmaceuticals, INC. | $39.43 | 2025 | Voquezna |
| Exact Sciences Corporation | $31.78 | 2025 | Cologuard Collection Kit |
| Axsome Therapeutics, INC. | $29.08 | 2024-2025 | Sunosi, Auvelity |
| Arbor Pharmaceuticals, INC. | $27.95 | 2019 | |
| Welch Allyn | $24.38 | 2021 | |
| Recor Medical INC | $17.79 | 2024 | Paradise Renal Denervation System |
| Verona Pharma, INC. | $16.48 | 2025 | Ohtuvayre |
| Idorsia Pharmaceuticals US INC | $15.80 | 2023 | Quviviq |
| Sanofi-Aventis U.S. LLC | $11.76 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taylor Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.